Published in:
01-04-2022 | Sarcoidosis | ORIGINAL ARTICLE
Diagnostic utility of fusion 18F-fluorodeoxyglucose positron emission tomography/cardiac magnetic resonance imaging in cardiac sarcoidosis
Authors:
Mana Okune, MD, Masakazu Yasuda, MD, Naoko Soejima, MD, Yoshinori Kagioka, MD, Kazuyoshi Kakehi, MD, Takayuki Kawamura, MD, Kohei Hanaoka, PhD, Hayato Kaida, MD, Kazunari Ishii, MD, Gaku Nakazawa, MD, Shunichi Miyazaki, MD, Yoshitaka Iwanaga, MD
Published in:
Journal of Nuclear Cardiology
|
Issue 2/2022
Login to get access
Abstract
Background
Although each 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) and cardiac magnetic resonance (CMR) imaging with late gadolinium enhancement (LGE) has been used to diagnose cardiac sarcoidosis (CS), active CS is still misdiagnosed.
Methods
Active CS, diagnosed by PET alone, was defined as focal or focal on diffuse FDG uptake pattern. In fusion PET/CMR imaging, using a regional analysis with AHA 17-segment model, the patients were categorized into four groups: (1) PET−/LGE−, (2) PET+/LGE−, (3) PET+/LGE+, and (4) PET−/LGE+. PET+/LGE+ was defined as active CS.
Results
74 Patients with suspected CS were enrolled. Between PET alone and fusion PET/CMR imaging, 20 cases had mismatch evaluations of active CS, and most had diffuse or focal on diffuse FDG uptake pattern on PET alone imaging. 40 Patients fulfilled the 2016 the Japanese Circulation Society diagnostic criteria for CS. The interobserver diagnostic agreement was excellent (κ statistics 0.89) and the overall accuracy for diagnosing CS was 87.8% in fusion PET/CMR imaging, which were superior to those in PET alone imaging (0.57 and 82.4%, respectively). In a sub-analysis of diffuse and focal on diffuse patterns, the agreement (κ statistics 0.86) and overall accuracy (81.8%) in fusion PET/CMR imaging were still better.
Conclusions
Fusion PET/CMR imaging with regional analysis offered reliable and accurate diagnosis of CS, covering low diagnostic area by FDG-PET alone.